Cipla USA, Inc. recalls Nilotinib Capsules
FDA Class III
FDA classified this recall as Class III: the product is unlikely to cause health problems but breaks the agency's rules (a labeling mistake, for example).
- Hazard
- Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
- Products
-
- Nilotinib Capsules
- Company
- Cipla USA, Inc.
- Where it was sold
-
U.S.A. Nationwide
Nationwide
- Units affected
- 164 cartons
- About this recall
- Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17